#USA #Onkos Surgical #NanoCept #Parsippany-Troy Hills #Total Femoral

Onkos Surgical’s Innovative Expansion in Orthopaedics

Onkos Surgical has taken a significant leap in improving patient outcomes with the announcement of the ELEOSTM Total Femoral Adapter. This new product incorporates NanoCept® Antibacterial Technology, which is set to provide safer options for patients who require total femoral replacements, a procedure notorious for its complexity and associated risks.

The introduction of this cutting-edge technology builds upon the prior success of NanoCept, which was initially made available on ELEOS implants used in reconstructive surgeries for complex knee and hip issues. Since its release in December 2024, over 500 patients have already benefitted from implants featuring this antibacterial technology. With the launch of the Total Femoral Adapter, Onkos Surgical aims to broaden the scope for patients undergoing complete femoral replacement surgery.

Dr. Julia Visgauss, Chief of the Orthopaedic Oncology Division at Duke Health, emphasized the importance of this innovation. She highlighted that many patients requiring total femoral replacements are already immunocompromised, making the presence of antibacterial implants a critical factor in their recovery journey. "Anything we can do to reduce risk and improve outcomes can make a meaningful difference in their recovery and quality of life," stated Dr. Visgauss, who has actively participated in post-market studies concerning NanoCept.

In an exciting development, the ELEOS Total Femoral Adapter is also notable for being the first of its kind to be manufactured and coated at the newly established NanoCept Innovation Center in Bridgewater, New Jersey. This facility marks an ambitious stride in Onkos's ongoing mission to enhance the availability of innovative solutions for complex orthopaedic issues.

According to Patrick Treacy, CEO and Co-Founder of Onkos Surgical, the launch of this product is a major milestone in their mission. He expressed that the development of solutions like the Total Femoral Replacement represents not just growth for the company but also a commitment to supporting some of the most vulnerable patients in the sector of orthopaedic oncology and revision procedures.

Onkos is dedicated to advancing the capabilities of its NanoCept Innovation Center. Plans are already underway to apply the antibacterial coating to additional ELEOS products in the upcoming months. This expansion reflects Onkos’s commitment to enhancing the world of orthopaedic solutions through innovative technologies.

About NanoCept®

Onkos Surgical received De Novo market authorization from the FDA in April 2024 for the NanoCept Antibacterial Technology used with the ELEOS™ Limb Salvage System. Preclinical studies have indicated an impressive 99.999% kill rate of bacteria typically encountered in surgical settings, setting the stage for improved patient safety. However, it's important to clarify that this coating is not a remedy for existing infections nor a guaranteed prevention of future infections. The clinical benefits of bacterial reduction have yet to be validated through human trials.

In conclusion, the introduction of the Total Femoral Adapter signifies not only technological healing in orthopaedics but also a forward-looking vision towards patient-centered care in complex medical procedures. As Onkos continues to innovate and expand its offerings, patient confidence is expected to grow, paving the way for enhanced recovery trajectories in orthopaedic surgeries.